{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:57:12Z","timestamp":1768568232964,"version":"3.49.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.neurobiolaging.2011.09.008","type":"journal-article","created":{"date-parts":[[2011,10,14]],"date-time":"2011-10-14T22:29:01Z","timestamp":1318631341000},"page":"S64-S66","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Clinical trial methodologies for disease-modifying therapeutic approaches"],"prefix":"10.1016","volume":"32","author":[{"given":"Paul S.","family":"Aisen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/alzrt2","article-title":"Alzheimer's disease therapeutic research: the path forward","volume":"1","author":"Aisen","year":"2009","journal-title":"Alzheimers Res. Ther"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","article-title":"Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans","volume":"6","author":"Aisen","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nm1438","article-title":"Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo","volume":"12","author":"Bateman","year":"2006","journal-title":"Nat. Med"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2011.09.008_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin. Neuropharmacol"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458011003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458011003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T09:58:08Z","timestamp":1543485488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458011003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":8,"alternative-id":["S0197458011003459"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.008","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}